血液恶性肿瘤患者中MTHFR基因多态性与大剂量甲氨蝶呤血液毒性相关性的Meta分析
x

请在关注微信后,向客服人员索取文件

篇名: 血液恶性肿瘤患者中MTHFR基因多态性与大剂量甲氨蝶呤血液毒性相关性的Meta分析
TITLE: Hematotoxicity Correlation of MTHFR Gene Polymorphism with High-dose of Methotrexate in Hematological Neoplasm Patients :A Meta-analysis
摘要: 目的:系统评价血液恶性肿瘤患者中亚甲基四氢叶酸还原酶(MTHFR)C677T及A1298C多态性与大剂量甲氨蝶呤(HD-MTX)血液系统不良事件的相关性。方法:系统检索Medline、Embase、ClinicalTrials.gov、中国学术期刊网络出版总库、万方数据库、中国生物医学文献数据库,收集采用HDMTX治疗血液恶性肿瘤涉及MTHFRC677T及A1298C基因多态性的队列研究,时限均为自建库起至2018年3月。对符合纳入标准的文献进行资料提取,并采用纽卡斯尔-渥太华量表进行质量评价后,应用RevMan5.3软件对不同遗传模型下HDMTX血液系统不良事件进行Meta分析。结果:共纳入25项队列研究,其中23项研究关注MTHFRC677T位点(1858例患者)、16项研究关注MTHFRA1298C位点(1088例患者)。Meta分析结果表明,MTHFRC677T突变型显著增加了血液毒性[TT/CTvs.CC:OR=1.57,95%CI(1.12,2.20),P=0.009;TTvs.CT/CC:OR=2.19,95%CI(1.49,3.23),P<0.001;Tvs.C:OR=1.34,95%CI(1.03,1.74),P=0.03]、严重血液毒性[TT/CTvs.CC:OR=2.33,95%CI(1.43,3.81),P<0.001]的发生风险,具体包括增加了白细胞减少[TT/CTvs.CC:OR=1.37,95%CI(1.02,1.82),P=0.03]、严重白细胞减少[TT/CTvs.CC:OR=1.63,95%CI(1.03,2.56),P=0.04]、严重粒细胞减少[TT/CTvs.CC:OR=2.26,95%CI(1.50,3.39),P<0.001]的发生风险;MTHFRA1298C突变型显著降低了严重血液毒性[CC/ACvs.AA:OR=0.17,95%CI(0.04,0.76),P=0.02]的发生风险,具体包括降低了白细胞减少[CC/ACvs.AA:OR=0.68,95%CI(0.48,0.97),P=0.03;CCvs.AC/AA:OR=0.28,95%CI(0.14,0.59),P<0.001]、严重白细胞减少[CC/ACvs.AA:OR=0.43,95%CI(0.19,0.97),P=0.04]的发生风险。结论:在血液恶性肿瘤患者中,MTHFRC677T突变型可能增加HDMTX血液毒性发生风险,包括白细胞减少以及粒细胞减少;而MTHFRA1298C突变型则可能降低HDMTX血液毒性发生风险,包括白细胞减少。
ABSTRACT: OBJECTIVE:To systematically evaluate the c orrelation of methylenetetra hydrofolate reductase (MTHFR)C677T and A 1298C gene polymorphisms with blood system adverse events induced by high-dose of methotrexate (HDMTX). METHODS : Retrieved from Medline ,Embase,Clinical Trials.gov ,CNKI,Wanfang database ,CBM,cohort studies about MTHFR gene polymorphism in hematological neoplasm treated by HDMTX were collected from inceptions to March 2018. After data extraction of included literatures ,quality evaluation with Newcastle Ottawa scale ,Meta-analysis was performed for adverse events of blood system induced by HDMTX in different genetic models with Rev Man 5.3 software. RESULTS :Totally 25 cohort studies were included,23 studies of which were related to MTHFR C677T site (including 1 858 patients)and 16 studies related to MTHFR A1298C site (including 1 088 patients). Results of Meta-analysis showed that MTHFR C677T mutation type significantly increased the risk of hematotoxicity [TT/CT vs. CC :OR=1.57,95%CI(1.12,2.20),P=0.009;TT vs. CT/CC :OR=2.19,95%CI(1.49, 3.23),P<0.001;T vs. C :OR=1.34,95%CI(1.03,1.74), P=0.03] and severe hematotoxicity [TT/CT vs. CC :OR=m 2.33,95%CI(1.43,3.81),P<0.001],including leukopenia [TT/CT vs. CC :OR=1.37,95%CI(1.02,1.82),P=0.03], severe leukopenia [TT/CT vs. CC :OR=1.63,95%CI(1.03, 010-82265810。E-mail:zhao_rongsheng@163.com 2.56),P=0.04],severe gra nulopenia [TT/CT vs. CC :OR= ·2.26,95%CI(1.50,3.39),P<0.001]. The mutation genotypes of MTHFR A1298C significantly decreased the risk of severe hematotoxicity [CC/AC vs. AA :OR=0.17,95%CI(0.04,0.76),P=0.02],including leukopenia [CC/AC vs. AA :OR=0.68, 95%CI(0.48,0.97),P=0.03;CC vs. AC/AA :OR=0.28,95%CI(0.14,0.59),P<0.001] and severe leukopenia [CC/AC vs. AA:OR=0.43,95%CI(0.19,0.97),P=0.04]. CONCLUSIONS :Among patients with hematological neoplasms ,MTHFR C677T mutation may significantly increase the risk of hematotoxicity by HDMTX including the risk of leukopenia and granulopenia ;while MTHFR A1298C may reduce the risk of hematotoxicity by HDMTX ,including the risk of leukopenia.
期刊: 2020年第31卷第07期
作者: 刘爽,宋再伟,易湛苗,赵荣生
AUTHORS: LIU Shuang ,SONG Zaiwei ,YI Zhanmiao ,ZHAO Rongsheng
关键字: 亚甲基四氢叶酸还原酶;基因多态性;大剂量甲氨蝶呤;血液恶性肿瘤;安全性;Meta分析
KEYWORDS: Methylenetetrahydrofolate reductase ;Gene polymorphisms ;High-dose methotrexate ;Hematological neoplasms ;
阅读数: 344 次
本月下载数: 13 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!